Helsinn Group

Dr. Melanie Rolli shares her thoughts on what Helsinn has achieved in the first half of the year. #ceotalks

Today marks  #EarthOvershootDay – the day when humanity's demand for ecological resources exceeds what the Earth can regenerate in one year. At Helsinn, we recognize the interconnectedness of human health and planetary well-being. As a carbon neutral company, we are deeply committed to minimizing our environmental footprint and contributing to a sustainable future. But our responsibility extends beyond our operations. We invite you to join us in reflecting on Earth Overshoot Day and taking steps to #MoveTheDate. Let's embrace sustainable practices, advocate for change, and work together to protect the resources that sustain us all. Together, we can create a healthier planet for ourselves and for future generations. Click here to find out more about our commitment to sustainability: https://lnkd.in/dhfYtigK

Nausea and vomiting (NV) are common side effects of anticancer treatment, assessed in acute (first 24 hours), delayed (days 2-5), and long-delayed (beyond day 5) phases. Emerging data on certain antibody-drug conjugates (ADCs) suggest NV may persist well into the long-delayed phase, impacting patients’ quality of life and treatment continuity.   #seeCINVbetter #supportivecare #ADCs    

Evolving data on new antibody-drug conjugates (ADCs) suggests that some may cause nausea and vomiting lasting more than 5 days (referred to as “long-delayed CINV”). Administering guideline-recommended antiemetic prophylaxis is critical, especially considering the extended treatment duration for many patients. As uncontrolled CINV significantly increases the risk for CINV in subsequent cycles, appropriate upfront antiemetics when initiating ADCs are essential to optimize patient outcomes. #seeCINVbetter #supportivecare #ADCs         

We are pleased to announce that AKYNZEO® injection (fosnetupitant/palonosetron) is now available in the US in a ready-to-use vial. Dr. Melanie Rolli expresses her insights on this significant milestone. To find out more, read the full announcement here: https://lnkd.in/dnapPdkW #supportivecare

Our technical organization orchestrates a balanced mix of internal and external capabilities also for manufacturing and supply chain. At our state-of-the-art manufacturing facility in Ireland, we manufacture commercial solid and semisolid dosage forms and handle high-potency drugs. Analytical testing and QP release are run on site, as is the management of the global supply chain that reaches patients all around the globe. Learn more about our journey to in-house product manufacturing and supply: https://lnkd.in/ekCtvEJp #manufacturing

This is the future vision for Helsinn Group as explained by our #CEO Dr. Melanie Rolli. #transformation

Today, we have the opportunity to be on the ground and connect with the healthcare community at the MASCC Annual Meeting in Paris. We have the chance to explore the latest advances in #supportivecare to reinforce our commitment to improving patients' quality of life.   #MASCC24

Helsinn is committed to raising awareness of the importance of antiemetic guidelines. In synch with the #MASCC24 annual meeting, Helsinn reminds HCPs that MASCC/ESMO released new antiemetic guidelines. Key practice changing updates include recommended use of a triple combination of a NK1 receptor antagonist (RA), 5-HT3 RA and steroids prophylactically in situations where emetogenic potential is now considered at the high end of the moderate category (eg, for patients receiving carboplatin (AUC ≥ 5), for women <50 receiving oxaliplatin, for patients receiving ADCs such as trastuzumab-deruxtecan and sacituzumab-govitecan). #supportivecare #antiemetics #CINV

  Today marks the start of World Wellbeing Week! At Helsinn, we place a high value on the health and happiness of our employees. Take for instance, at Helsinn Birex Pharmaceuticals Ltd, Dublin, the annual employee wellbeing plans are holistically designed to enhance the health and wellness of all, with topics and initiatives as diverse as the employees to which they serve.  At the core of our wellness programme is health screening. Each year our employees in Ireland undergo a full medical screening and have the added options of attending onsite pop-up clinics that deliver flu vaccinations and a range of cancer and heart screening services. The 2024 Wellbeing Programme also allows employees to sign up for physical activities such as onsite Pilates classes, reflexology, massage and physiotherapy sessions. Employees can engage in financial health consultations with pension providers, mortgage lenders and personal taxes and attend onsite seminars in a range of topics related to mental health. #wellbeing